23 results on '"Budd, G. Thomas"'
Search Results
2. SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy.
3. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
4. Use of imaging studies for early-stage breast cancer at Cleveland Clinic.
5. Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
6. A single institution’s experience with the value of FDG-PET-CT imaging in patients with newly diagnosed stage IIB-IIIB breast cancer.
7. Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer.
8. Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases.
9. Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience.
10. Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
11. Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
12. Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.
13. Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study.
14. New graded prognostic index for breast cancer patients (pts) with brain metastases (BCBM).
15. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
16. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
17. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
18. Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.
19. Docetaxel, carboplatin, trastuzumab, and bevacizumab (TCH+B) for early-stage HER2/neu(+) breast cancer and bone marrow micrometastases.
20. Use of HER2 score correction for putative chromosome 17 (Chr-17) aneusomy to increase eligibility for anti-HER2 therapy.
21. Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status
22. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer
23. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.